Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
BMC Anesthesiol. 2022 May 30;22(1):168. doi: 10.1186/s12871-022-01707-4.
Appropriate placement of left-sided double-lumen endotracheal tubes (LDLTs) is paramount for optimal visualization of the operative field during thoracic surgeries that require single lung ventilation. Appropriate placement of LDLTs is therefore confirmed with fiberoptic bronchoscopy (FOB) rather than clinical assessment alone. Recent studies have demonstrated lung ultrasound (US) is superior to clinical assessment alone for confirming placement of LDLT, but no large trials have compared US to the gold standard of FOB. This noninferiority trial was devised to compare lung US with FOB for LDLT positioning and achievement of lung collapse for operative exposure.
This randomized, controlled, double-blind, noninferiority trial was conducted at the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand from October 2017 to July 2019. The study enrolled 200 ASA classification 1-3 patients that were scheduled for elective thoracic surgery requiring placement of LDLT. Study patients were randomized into either the FOB group or the lung US group after initial blind placement of LDLT. Five patients were excluded due to protocol deviation. In the FOB group (n = 98), fiberoptic bronchoscopy was used to confirm lung collapse due to proper positioning of the LDLT, and to adjust the tube if necessary. In the US group (n = 97), lung ultrasonography of four pre-specified zones (upper and lower posterior and mid-axillary) was used to assess lung collapse and guide adjustment of the tube if necessary. The primary outcome was presence of adequate lung collapse as determined by visual grading by the attending surgeon on scale from 1 to 4. Secondary outcomes included the time needed to adjust and confirm lung collapse, the time from finishing LDLT positioning to the grading of lung collapse, and intraoperative parameters such has hypotension or hypertension, hypoxia, and hypercarbia. The patient, attending anesthesiologist, and attending thoracic surgeon were all blinded to the intervention arm.
The primary outcome of lung collapse by visual grading was similar between the intervention and the control groups, with 89 patients (91.8%) in the US group compared to 83 patients (84.1%) in the FOB group (p = 0.18) experiencing adequate collapse. This met criteria for noninferiority per protocol analysis. The median time needed to confirm and adjust LDLT position in the US group was 3 min (IQR 2-5), which was significantly shorter than the median time needed to perform the task in the FOB group (6 min, IQR 4-10) (p = 0.002).
In selected patients undergoing thoracic surgery requiring LDLT, lung ultrasonography was noninferior to fiberoptic bronchoscopy in achieving adequate lung collapse and reaches the desired outcome in less time.
This study was registered at clinicaltrials.gov, NCT03314519 , Principal investigator: Kasana Raksamani, Date of registration: 19/10/2017.
在需要单肺通气的胸科手术中,左侧双腔气管导管(LDLT)的适当位置对于优化手术视野至关重要。因此,LDLT 的适当位置通过纤维支气管镜(FOB)而不是仅通过临床评估来确认。最近的研究表明,肺超声(US)在确认 LDLT 位置方面优于单独的临床评估,但尚无大型试验将 US 与 FOB 的金标准进行比较。本非劣效性试验旨在比较肺 US 与 FOB 用于 LDLT 定位和实现手术暴露所需的肺塌陷。
本随机、对照、双盲、非劣效性试验于 2017 年 10 月至 2019 年 7 月在泰国玛希隆大学诗里拉吉医院医学系进行。研究纳入了 200 名 ASA 分级 1-3 级的择期接受胸科手术且需要放置 LDLT 的患者。研究患者在最初盲置 LDLT 后随机分为 FOB 组或肺 US 组。由于方案偏离,有 5 名患者被排除。在 FOB 组(n=98)中,使用纤维支气管镜确认由于 LDLT 正确定位导致的肺塌陷,并在必要时调整导管。在 US 组(n=97)中,使用四个预先指定区域(上后、下后和腋中线)的肺超声评估肺塌陷,并在必要时指导导管调整。主要结局是术者根据 1 到 4 分的视觉分级来判断是否存在足够的肺塌陷。次要结局包括调整和确认肺塌陷所需的时间、完成 LDLT 定位到肺塌陷分级的时间以及术中参数(如低血压或高血压、缺氧和高碳酸血症)。患者、主管麻醉师和主管胸外科医师均对干预组不知情。
两组术者视觉分级的肺塌陷主要结局相似,US 组 89 例(91.8%)患者与 FOB 组 83 例(84.1%)患者的肺塌陷程度足够(p=0.18)。这符合方案分析的非劣效性标准。US 组确认和调整 LDLT 位置所需的中位数时间为 3 分钟(IQR 2-5),明显短于 FOB 组所需的中位数时间 6 分钟(IQR 4-10)(p=0.002)。
在接受需要 LDLT 的胸科手术的选定患者中,肺超声在实现足够的肺塌陷方面与纤维支气管镜相当,但达到所需结果的时间更短。
本研究在 clinicaltrials.gov 注册,NCT03314519,主要研究者:Kasana Raksamani,登记日期:2017 年 10 月 19 日。